Study summary

An mRNA CAR T therapy helped two thirds at 3 months

Descartes-08 phase 2b · Phase 2b · Results presented through 2026; phase 3 data expected early 2027

66.7%responded at 3 months, vs 27.3% with placebo (subgroup)

What was tested

Descartes-08, an mRNA CAR T-cell therapy against BCMA given as outpatient infusions without chemotherapy, against placebo in generalized myasthenia gravis.

What they found

In a reported subgroup, 66.7% responded at 3 months vs 27.3% with placebo.
Responses lasted about a year for many.

What it means

Could offer long drug-free remission. The phase 3 AURORA trial will confirm.

Myasthenia Gravis News ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.